ShareValue scores for 0P5I.LSE: Valuation 49, Quality 17, Growth 50, Health 34.

0P5I.LSE
LSE

Mauna Kea Technologies SA

£0.00(-2.33%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

2% to 18%
Valuation
49
Fair Value
Price vs Value
Quality
17
Weak
Business Strength
Growth
50
Moderate
Revenue & Earnings
Health
34
Stressed
Financial Stability
Momentum
26
Bearish
Price Trend

Company Details

About

Mauna Kea Technologies SA manufactures and sells medical devices in Europe and internationally. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform that enables unique in vivo cellular visualization, allowing doctors to monitor disease evolution over time, evaluate reactions as they occur, classify areas of uncertainty, guide surgical interventions, and help diagnose and treat patients. The company was incorporated in 2000 and is headquartered in Paris, France.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026